Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 29102 | 193 | 38.6 | 91% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
| 441 | 3 | TRAIL//SURVIVIN//APOPTOSIS | 26474 |
| 306 | 2 | TRAIL//SURVIVIN//APOPTOSIS | 18497 |
| 29102 | 1 | M65//M30//CYTOKERATIN 18 | 193 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | M65 | authKW | 2531427 | 10% | 80% | 20 |
| 2 | M30 | authKW | 2027222 | 16% | 41% | 31 |
| 3 | CYTOKERATIN 18 | authKW | 1041351 | 16% | 21% | 31 |
| 4 | M65 ELISA | authKW | 632859 | 2% | 100% | 4 |
| 5 | SERUM M30 LEVEL | authKW | 632859 | 2% | 100% | 4 |
| 6 | SERUM M65 LEVEL | authKW | 632859 | 2% | 100% | 4 |
| 7 | M30 ELISA | authKW | 474644 | 2% | 100% | 3 |
| 8 | CLIN EXPT PHARMACOL CEP GRP | address | 355982 | 2% | 75% | 3 |
| 9 | M30 APOPTOSENSE | authKW | 316429 | 1% | 100% | 2 |
| 10 | M30 LEVEL | authKW | 316429 | 1% | 100% | 2 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Gastroenterology & Hepatology | 1271 | 25% | 0% | 48 |
| 2 | Oncology | 833 | 35% | 0% | 67 |
| 3 | Medical Laboratory Technology | 58 | 3% | 0% | 6 |
| 4 | Pharmacology & Pharmacy | 45 | 11% | 0% | 22 |
| 5 | Medicine, Research & Experimental | 36 | 6% | 0% | 12 |
| 6 | Virology | 32 | 4% | 0% | 7 |
| 7 | Cell Biology | 29 | 8% | 0% | 16 |
| 8 | Pathology | 29 | 4% | 0% | 8 |
| 9 | Critical Care Medicine | 7 | 2% | 0% | 3 |
| 10 | Infectious Diseases | 7 | 3% | 0% | 5 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | CLIN EXPT PHARMACOL CEP GRP | 355982 | 2% | 75% | 3 |
| 2 | CLIN EXPT PHARMACOL GRP | 242310 | 6% | 14% | 11 |
| 3 | ATRIUM HEERLEN | 158215 | 1% | 100% | 1 |
| 4 | CANC ENABLING SCISTEM CELL LEUKAEMIA PRO | 158215 | 1% | 100% | 1 |
| 5 | CLIN EPIDEMIOL ASSESSMENT TECHNOL | 158215 | 1% | 100% | 1 |
| 6 | CLIN EXP PHARMACOL GRP | 158215 | 1% | 100% | 1 |
| 7 | CYTOL IMMUNOPATHOL | 158215 | 1% | 100% | 1 |
| 8 | DEP MED GASTROENTEROL HEPATOL | 158215 | 1% | 100% | 1 |
| 9 | IMMUNOL TUMEURS HUMAINES INTERACT EFFECTEUIS | 158215 | 1% | 100% | 1 |
| 10 | KLINIKUM ALLGEMEINE GEFASS TRANSPLANT CHIRURG | 158215 | 1% | 100% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | CELL AND BIOSCIENCE | 1931 | 1% | 1% | 2 |
| 2 | HEPATITIS MONTHLY | 1774 | 2% | 0% | 3 |
| 3 | LIVER INTERNATIONAL | 1553 | 3% | 0% | 5 |
| 4 | TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI | 1116 | 1% | 0% | 2 |
| 5 | ARAB JOURNAL OF GASTROENTEROLOGY | 1104 | 1% | 1% | 1 |
| 6 | BRITISH JOURNAL OF CANCER | 1058 | 6% | 0% | 11 |
| 7 | CANCER GENOMICS & PROTEOMICS | 751 | 1% | 0% | 1 |
| 8 | JOURNAL OF VIRAL HEPATITIS | 640 | 2% | 0% | 3 |
| 9 | TUMOR BIOLOGY | 637 | 3% | 0% | 5 |
| 10 | CELL DEATH & DISEASE | 599 | 2% | 0% | 3 |
Author Key Words |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | M65 | 2531427 | 10% | 80% | 20 | Search M65 | Search M65 |
| 2 | M30 | 2027222 | 16% | 41% | 31 | Search M30 | Search M30 |
| 3 | CYTOKERATIN 18 | 1041351 | 16% | 21% | 31 | Search CYTOKERATIN+18 | Search CYTOKERATIN+18 |
| 4 | M65 ELISA | 632859 | 2% | 100% | 4 | Search M65+ELISA | Search M65+ELISA |
| 5 | SERUM M30 LEVEL | 632859 | 2% | 100% | 4 | Search SERUM+M30+LEVEL | Search SERUM+M30+LEVEL |
| 6 | SERUM M65 LEVEL | 632859 | 2% | 100% | 4 | Search SERUM+M65+LEVEL | Search SERUM+M65+LEVEL |
| 7 | M30 ELISA | 474644 | 2% | 100% | 3 | Search M30+ELISA | Search M30+ELISA |
| 8 | M30 APOPTOSENSE | 316429 | 1% | 100% | 2 | Search M30+APOPTOSENSE | Search M30+APOPTOSENSE |
| 9 | M30 LEVEL | 316429 | 1% | 100% | 2 | Search M30+LEVEL | Search M30+LEVEL |
| 10 | CK18 | 304253 | 3% | 38% | 5 | Search CK18 | Search CK18 |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | SEN, F , YILDIZ, I , ODABAS, H , TAMBAS, M , KILIC, L , KARADENIZ, A , ALTUN, M , EKENEL, M , SERILMEZ, M , DURANYILDIZ, D , ET AL (2015) DIAGNOSTIC VALUE OF SERUM M30 AND M65 IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA.TUMOR BIOLOGY. VOL. 36. ISSUE 2. P. 1039 -1044 | 21 | 75% | 1 |
| 2 | TAS, F , KARABULUT, S , YILDIZ, I , DURANYILDIZ, D , (2014) CLINICAL SIGNIFICANCE OF SERUM M30 AND M65 LEVELS IN PATIENTS WITH BREAST CANCER.BIOMEDICINE & PHARMACOTHERAPY. VOL. 68. ISSUE 8. P. 1135 -1140 | 19 | 83% | 1 |
| 3 | YAMAN, E , COSKUN, U , SANCAK, B , BUYUKBERBER, S , OZTURK, B , BENEKLI, M , (2010) SERUM M30 LEVELS ARE ASSOCIATED WITH SURVIVAL IN ADVANCED GASTRIC CARCINOMA PATIENTS.INTERNATIONAL IMMUNOPHARMACOLOGY. VOL. 10. ISSUE 7. P. 719-722 | 17 | 89% | 20 |
| 4 | OZTURK, B , COSKUN, U , SANCAK, B , YAMAN, E , BUYUKBERBER, S , BENEKLI, M , (2009) ELEVATED SERUM LEVELS OF M30 AND M65 IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK TUMORS.INTERNATIONAL IMMUNOPHARMACOLOGY. VOL. 9. ISSUE 5. P. 645-648 | 15 | 100% | 24 |
| 5 | YILDIZ, I , SEN, F , KILIC, L , KESKIN, S , DURANYILDIZ, D , BILGIN, E , DISCI, R , EKENEL, M , DARENDELILER, E , BAVBEK, S , ET AL (2013) SERUM M65 AS A BIOMARKER FOR METASTATIC RENAL CELL CARCINOMA.CLINICAL GENITOURINARY CANCER. VOL. 11. ISSUE 3. P. 290-296 | 19 | 73% | 5 |
| 6 | TAS, F , KARABULUT, S , BILGIN, E , SEN, F , YILDIZ, I , TASTEKIN, D , CIFTCI, R , DURANYILDIZ, D , (2013) CLINICAL SIGNIFICANCE OF SERUM M30 AND M65 LEVELS IN METASTATIC PANCREATIC ADENOCARCINOMA.TUMOR BIOLOGY. VOL. 34. ISSUE 6. P. 3529-3536 | 18 | 78% | 2 |
| 7 | CEVATEMRE, B , ULUKAYA, E , SARIMAHMUT, M , ORAL, AY , FRAME, FM , (2015) THE M30 ASSAY DOES NOT DETECT APOPTOSIS IN EPITHELIAL-DERIVED CANCER CELLS EXPRESSING LOW LEVELS OF CYTOKERATIN 18.TUMOR BIOLOGY. VOL. 36. ISSUE 9. P. 6857 -6865 | 23 | 58% | 0 |
| 8 | BILICI, A , USTAALIOGLU, BBO , ERCAN, S , ORCUN, A , SEKER, M , SALEPCI, T , GUMUS, M , (2011) IS THERE ANY IMPACT OF PLASMA M30 AND M65 LEVELS ON PROGRESSION-FREE SURVIVAL OF PATIENTS WITH ADVANCED GASTRIC CANCER?.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 68. ISSUE 2. P. 309-316 | 17 | 77% | 11 |
| 9 | DIVE, C , SMITH, RA , GARNER, E , WARD, T , ST GEORGE-SMITH, S , CAMPBELL, F , GREENHALF, W , GHANEH, P , NEOPTOLEMOS, JP , (2010) CONSIDERATIONS FOR THE USE OF PLASMA CYTOKERATIN 18 AS A BIOMARKER IN PANCREATIC CANCER.BRITISH JOURNAL OF CANCER. VOL. 102. ISSUE 3. P. 577 -582 | 18 | 69% | 26 |
| 10 | OYAMA, K , FUSHIDA, S , KINOSHITA, J , OKAMOTO, K , MAKINO, I , NAKAMURA, K , HAYASHI, H , INOKUCHI, M , NAKAGAWARA, H , TAJIMA, H , ET AL (2013) SERUM CYTOKERATIN 18 AS A BIOMARKER FOR GASTRIC CANCER.CLINICAL AND EXPERIMENTAL MEDICINE. VOL. 13. ISSUE 4. P. 289-295 | 17 | 65% | 12 |
Classes with closest relation at Level 1 |